L Lactate Dehydrogenase
Background
L-lactate dehydrogenase (LDH) is a pivotal enzyme found in nearly all living cells, playing a crucial role in cellular metabolism. It catalyzes the reversible conversion of pyruvate to L-lactate, a fundamental step in anaerobic glycolysis. This enzymatic reaction is essential for regenerating nicotinamide adenine dinucleotide (NAD+) from its reduced form (NADH), thereby allowing glycolysis to continue producing adenosine triphosphate (ATP) to meet cellular energy demands, particularly when oxygen is limited.
Biological Basis
LDH typically exists as a tetrameric enzyme, formed from combinations of two distinct protein subunits: heart (H) and muscle (M). These subunits combine in various ratios to create five major isoenzymes: LDH-1 (HHHH), LDH-2 (HHHM), LDH-3 (HHMM), LDH-4 (HMMM), and LDH-5 (MMMM). Each isoenzyme exhibits a unique tissue distribution and catalytic preference, reflecting the specific metabolic environment of different organs. For example, LDH-1 is highly concentrated in heart muscle and red blood cells, where it primarily converts lactate back to pyruvate, while LDH-5 is abundant in skeletal muscle and liver, favoring the conversion of pyruvate to lactate. This isoenzyme diversity allows for fine-tuning of metabolic pathways according to tissue-specific needs.
Clinical Relevance
Elevated levels of LDH in the blood serum are a general indicator of tissue damage or disease, as the enzyme is released into circulation when cells are injured or destroyed. While not specific to a single organ, the pattern of LDH isoenzymes can provide more localized diagnostic information. For instance, an increase in LDH-1 can suggest conditions such as myocardial infarction or hemolytic anemia, whereas elevated LDH-5 often points to liver disease or skeletal muscle injury. LDH levels are routinely monitored in clinical settings to aid in the diagnosis, assessment of disease severity, and prognosis of various conditions, including heart attacks, liver and kidney diseases, muscular dystrophies, and certain cancers. In oncology, LDH often serves as a valuable biomarker for tumor burden and as an indicator of treatment response.
Social Importance
The measurement of LDH holds significant social importance in public health and clinical diagnostics. Its role as a broad indicator of cellular injury makes it a valuable, cost-effective tool for initial disease screening and for monitoring the progression of illnesses. By providing early clues to underlying physiological disturbances, LDH testing contributes to more timely diagnosis and intervention strategies, potentially leading to improved patient outcomes across a wide array of health conditions. Furthermore, continued research into the genetic variations influencing LDH activity and isoenzyme expression could pave the way for more precise diagnostic markers and the development of novel therapeutic approaches for metabolic disorders and various pathologies, thereby advancing our understanding of human health and disease.
Methodological and Statistical Constraints
Genetic studies, including those for enzyme levels, frequently face limitations related to statistical power and the comprehensiveness of genomic coverage. Many associations, particularly those with modest effect sizes, may remain undetected due to insufficient sample sizes or the partial representation of genetic variation on genotyping arrays, which may miss causal variants not in strong linkage disequilibrium with genotyped single nucleotide polymorphisms (SNPs). [1] Furthermore, the quality of genotype imputation, a critical step for increasing genomic coverage, can vary, leading to some SNPs being excluded from analyses or having lower confidence, thereby potentially obscuring true associations. [2] Replication across independent cohorts is essential for validating findings, yet it can be challenging due to differences in linkage disequilibrium patterns between populations, the presence of multiple causal variants within a gene, or variations in study design, making it difficult to confirm initial discoveries. [2] The use of sex-pooled analyses can also overlook sex-specific genetic effects, while varied cohort recruitment strategies, such as population-based versus nested case-control designs, may introduce biases that affect the generalizability of findings. [3]
Ancestry, Phenotypic Variability, and Generalizability
The generalizability of genetic findings is often constrained by the demographic characteristics of the study populations. Many large-scale genetic studies have historically focused predominantly on individuals of European ancestry, with limited inclusion of other ethnic groups, such as Indian Asian cohorts. [2] This limited diversity means that genetic associations identified in one population may not translate directly to others due to differences in allele frequencies, linkage disequilibrium structures, and genetic architectures, potentially leading to an incomplete understanding of genetic influences across the global population. [2] Moreover, the accurate and consistent measurement of enzyme levels and other phenotypes across diverse studies presents a significant challenge. Variations in laboratory assays, demographic profiles of participants, and environmental exposures can introduce methodological differences and confounders that affect observed enzyme levels, complicating meta-analyses and the interpretation of genetic effects. [2] The biological relevance of findings can also be context-dependent, as genetic variants may exert their effects differently based on environmental factors or specific tissue expression, requiring careful consideration of the study's design and the biological context of the measurement. [4]
Unaccounted Environmental Factors and Remaining Heritability
A substantial limitation in understanding the genetic basis of complex traits, including enzyme levels, is the often-unexplored role of gene-environment interactions. Environmental factors, such as diet, lifestyle, and exposure to specific substances like alcohol and smoking, are known to modulate genetic predispositions and can significantly influence enzyme activity. [2] Studies that do not explicitly investigate these interactions may miss crucial insights into how genetic variants exert their effects under different conditions, leading to an incomplete picture of disease etiology. Furthermore, despite the identification of numerous genetic loci, individual SNPs or even sets of clinical covariates often explain only a small proportion of the total phenotypic variance, highlighting the pervasive "missing heritability" problem. [5] This suggests that a large fraction of the genetic and environmental influences on traits remains unexplained, pointing to the need for more comprehensive genomic approaches, including rare variant analyses, and a deeper exploration of gene-environment interactions to fully elucidate the genetic architecture of enzyme levels and other complex traits. Additionally, some biomarkers may prove uninformative in genetic association studies, yielding no genome-wide significant associations, which underscores the complexity of these traits and the need for further research into their underlying biological mechanisms. [2]
Variants
Variants across several genes associated with immune regulation, inflammation, and cellular metabolism offer insights into their potential impact on l-lactate dehydrogenase activity. This enzyme is a critical indicator of cellular damage, metabolic stress, and altered energy production, often elevated in inflammatory conditions or tissue injury. Understanding these genetic influences helps elucidate the complex interplay between immune responses, metabolic pathways, and cellular health.
Genes such as CD163L1, CD163, and STAB1 encode scavenger receptors, predominantly expressed on macrophages and endothelial cells, which are crucial for clearing cellular debris, pathogens, and modulating inflammatory processes. CD163 is particularly known as a marker for M2 macrophages, which are involved in anti-inflammatory responses and tissue repair. Variants like rs74754250, rs4072797, and rs34985304 in CD163L1, and rs6488345 and rs4883263 in CD163, may alter the expression or function of these receptors, thereby influencing macrophage polarization and activity. Similarly, the rs150956780 variant in STAB1 could impact its role in clearing inflammatory molecules. CSF1 (Colony Stimulating Factor 1), with variant rs333947, is a key cytokine regulating macrophage development and function; alterations here could profoundly affect the immune landscape and inflammatory state. [6] Such immune dysregulation can lead to increased cellular stress and turnover, contributing to elevated l-lactate dehydrogenase levels, a common biomarker for cellular damage and inflammation. [7] The shared variant rs117692263 and the intergenic variant rs7305678 between CD163 and GAPDHP31 suggest complex regulatory interactions that could influence both immune and metabolic pathways.
Further impacting immune responses are genes like LILRB5, HLA-DQB1, and NINJ1. The LILRB5 gene, with variants such as rs12975366 and rs393600, encodes a leukocyte immunoglobulin-like receptor that modulates immune cell activation and signaling, helping to fine-tune immune responses. Alterations in LILRB5 function could lead to imbalances in immune cell activity, potentially contributing to chronic inflammation. Similarly, HLA-DQB1, represented by variant rs17412833, is a major histocompatibility complex (MHC) class II gene essential for presenting antigens to T-cells, initiating adaptive immunity. Polymorphisms in HLA genes are known to influence susceptibility to autoimmune diseases and overall immune system responsiveness. [8] Changes in immune regulation can impact cellular metabolism, as activated immune cells often rely on glycolysis, potentially influencing l-lactate dehydrogenase activity. Furthermore, NINJ1 (Ninjurin 1), with variants rs7033638 and rs12342201, is a cell adhesion molecule increasingly recognized for its role in inflammation and cell death pathways, including pyroptosis. Dysregulation of NINJ1 could lead to aberrant cell death, releasing intracellular contents like l-lactate dehydrogenase into circulation, serving as a marker for tissue damage. [2]
The region encompassing GAPDHP31 and NIFKP3, featuring variant rs917863, is particularly relevant to cellular metabolism. GAPDHP31 is a pseudogene related to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a crucial enzyme in the glycolytic pathway responsible for producing pyruvate and, indirectly, lactate. While pseudogenes do not encode functional proteins themselves, they can influence the expression or stability of their functional counterparts, such as GAPDH, through various regulatory mechanisms including microRNA sponging or transcriptional interference. Therefore, variants like rs917863 in this pseudogene region could indirectly impact the rate of glycolysis and the production of lactate. Enhanced glycolysis and subsequent lactate production, often seen in conditions of cellular stress, hypoxia, or rapid proliferation, directly relate to the activity of l-lactate dehydrogenase. Understanding these genetic influences on metabolic pathways is crucial for interpreting biomarkers and disease mechanisms. [9] Such genetic variations can represent protein quantitative trait loci (pQTLs), affecting protein levels and cellular processes. [6]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs74754250 rs4072797 rs34985304 |
CD163L1 | l lactate dehydrogenase measurement |
| rs6488345 rs4883263 |
CD163 | l lactate dehydrogenase measurement |
| rs150956780 | STAB1 | l lactate dehydrogenase measurement |
| rs12975366 rs393600 |
LILRB5 | protein measurement matrix metalloproteinase 12 measurement kallikrein‐6 measurement ESAM/LAMA4 protein level ratio in blood FABP2/RBP2 protein level ratio in blood |
| rs917863 | GAPDHP31 - NIFKP3 | l lactate dehydrogenase measurement |
| rs117692263 | CD163L1, CD163 | creatine kinase measurement non-high density lipoprotein cholesterol measurement l lactate dehydrogenase measurement low density lipoprotein cholesterol measurement kallikrein-7 measurement |
| rs333947 | CSF1 | leukocyte quantity blood protein amount aspartate aminotransferase measurement creatine kinase measurement l lactate dehydrogenase measurement |
| rs17412833 | HLA-DQB1 | l lactate dehydrogenase measurement total cholesterol measurement low density lipoprotein cholesterol measurement |
| rs7305678 | CD163 - GAPDHP31 | apolipoprotein A 1 measurement high density lipoprotein cholesterol measurement l lactate dehydrogenase measurement creatine kinase measurement level of beta-enolase in blood |
| rs7033638 rs12342201 |
NINJ1 | l lactate dehydrogenase measurement |
References
[1] Kathiresan, S., et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nature Genetics, 2008.
[2] Yuan, X et al. "Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes." Am J Hum Genet, 2008.
[3] Yang, Q., et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Medical Genetics, 2007.
[4] Vasan, R. S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Medical Genetics, 2007.
[5] Pare, G., et al. "Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study." PLoS Genetics, 2008.
[6] Melzer, D et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genet, 2008.
[7] Benjamin, E. J., et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Medical Genetics, 2007.
[8] Saxena, R et al. "Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels." Science, 2007.
[9] Dixon, AL et al. "A whole-genome association study of global gene expression." Nat Genet; in press, 2007.